about
Optimizing treatment success in multiple sclerosisEvaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic ReviewOptimizing therapy early in multiple sclerosis: An evidence-based viewMultiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approachDetermination of baroreflex sensitivity during the modified Oxford maneuver by trigonometric regressive spectral analysisTherapeutic decisions in multiple sclerosis: moving beyond efficacyFunctional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disordersThe sensory channel of presentation alters subjective ratings and autonomic responses toward disgusting stimuli-Blood pressure, heart rate and skin conductance in response to visual, auditory, haptic and olfactory presented disgusting stimuli36 Months Pangaea: A 5-Year Non-Interventional Study of Safety, Efficacy and Pharmacoeconomic Data for Fingolimod Patients In Daily Clinical Practice.Laquinimod in the treatment of relapsing remitting multiple sclerosis.Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).Influence of ECG sampling frequency on spectral analysis of RR intervals and baroreflex sensitivity using the EUROBAVAR data set.Cardiovascular autonomic dysfunction in Parkinson's disease.The effects of venlafaxine on autonomic functions in healthy volunteers.Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.Trigonometric regressive spectral analysis reliably maps dynamic changes in baroreflex sensitivity and autonomic tone: the effect of gender and age.Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease (CAPTURE PD): Protocol for a Multicenter Study.Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.Treatment of dysautonomia in extrapyramidal disordersA 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.Risk-benefit assessment of glatiramer acetate in multiple sclerosis.Hes3 expression in the adult mouse brain is regulated during demyelination and remyelination.Cortisol awakening response is linked to disease course and progression in multiple sclerosis.Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination.[Axon-reflex based nerve fiber function assessment in the detection of autonomic neuropathy].Different responses of the retinal and cutaneous microcirculation to transient dysmetabolic conditions.The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis.Improving patient-physician dialog: commentary on the results of the MS Choices survey.Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetateDesign of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimodStatic posturography in aging and Parkinson's diseaseThe role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE).Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment.Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).Multiple sclerosis and the autonomic nervous system.The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis
P50
Q26771968-E2FCE9E5-4A67-4FFD-A84D-A7E84DE6B547Q26782408-54417ED0-9EF9-4EB9-933B-E7D9BFD4C84AQ26783070-2FBE0D61-987C-44B1-85A5-77FB34CECF56Q28080043-EC594565-8534-42A1-849E-88E2017DC2ABQ28477454-77BB143C-3EC3-4F64-BA5D-D0F0EBA57616Q28541039-312FBE72-CB2B-44A5-AA3E-91CE00D7E411Q28740884-370FDF3F-7B15-40AF-AD4E-2909561FD925Q30543931-80E2CEBD-D4EC-47DA-9FB4-8B407BC8D5E2Q31017255-5657313A-24B4-4112-A870-C1D381ED40B8Q31080085-40FA5CC0-C457-4770-95AF-B56A58338184Q31115496-CC4FA2E4-EED2-4530-B536-893DA38C7C70Q31150715-B6BDA955-AF4A-435D-916A-B4B5298931ACQ33157784-0D3FD82B-ABEB-4007-BCCA-17D9BEE88DC1Q33305624-54BA0325-D96B-4E4A-A3C2-094DB2AED2DFQ33642908-C33196A4-2247-484D-9E35-767A36F4B620Q33679925-8F48280B-19E2-41E7-90FF-42AD1CA71100Q33679925-E09DE3AF-3045-46BE-BFC0-A0332F4860EBQ33729353-EB033DA8-797D-4DB4-902F-679F22AB18EEQ33749104-AE58817A-CF0D-4915-88A0-464011482C55Q34409285-154EF3B1-4916-4B18-9B1D-C59C6339886FQ34459729-4B7A8743-F923-4D3A-B58D-AA96E0BC9496Q34519776-99CB9007-8CA5-4A20-9B78-7369F8D3C74EQ34519982-3EDA0469-CCA7-4BAE-AA00-19FC216E4CEDQ34683723-B1BBDC29-EE28-44F7-B482-5736DEE09C37Q35154391-BEDF6B3B-F691-46F9-95A4-0F6EF6030AB9Q35210255-56F9A2B4-51EF-4E0E-9C2E-BAB52E128D70Q35621053-7190EA03-4241-4A94-BD96-CB71AACDF3BBQ35666531-FE1B7C02-6E9C-45BE-9A3C-31A09A148AE5Q35672403-BDAA5090-9B9E-40A0-A8EF-9670BA1E53F6Q35780959-6AD6524A-A796-446A-A2F9-A843B2E18CA8Q35801041-141DDDA6-3F0A-4F3C-985E-2CC82BFC5A90Q36073992-2F41CABD-EA5C-4F16-B43C-F4E661542C8FQ36097847-F676B90E-976D-4DCC-8823-386E2A859836Q36142216-72705004-712A-444F-AF53-4AACB84BEF5BQ36246886-146DE581-712B-4D5E-B4E5-BF16A57735AAQ36253048-A29629F7-578C-48C1-8022-06DDBBD2787CQ36299405-E8975FB8-AF37-40AA-B5A7-010FD3DEF38DQ36324315-2CA65066-2662-4ED8-BD4F-FFC1C971D354Q36389706-471ADE89-F48F-48B7-8E8B-1EE3DAD96A8DQ36396160-FE3111AD-A0AA-499B-BC25-38753BDCD9F8
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tjalf Ziemssen
@ast
Tjalf Ziemssen
@en
Tjalf Ziemssen
@es
Tjalf Ziemssen
@nl
Tjalf Ziemssen
@sl
type
label
Tjalf Ziemssen
@ast
Tjalf Ziemssen
@en
Tjalf Ziemssen
@es
Tjalf Ziemssen
@nl
Tjalf Ziemssen
@sl
prefLabel
Tjalf Ziemssen
@ast
Tjalf Ziemssen
@en
Tjalf Ziemssen
@es
Tjalf Ziemssen
@nl
Tjalf Ziemssen
@sl
P214
P106
P1153
6602879721
P21
P214
P2798
P31
P3835
tjalf-ziemssen2
P4012
P496
0000-0001-8799-8202
P734
P735
P7859
viaf-37770758